文献速递垂体与肾上腺疾病

COVID-19死亡者垂体激素基因受抑制,与腺体内病毒检出无关

Suppression of Pituitary Hormone Genes in Subjects Who Died From COVID-19 Independently of Virus Detection in the Gland.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究检测23例COVID-19死亡者与12例对照者垂体中的SARS-CoV-2基因组和抗原,14/23(61%)COVID-19垂体阳性,对照组未检出;病毒阳性腺体可见I型干扰素信号激活及中性粒细胞、细胞毒性细胞评分升高,所有COVID-19病例(无论病毒是否阳性)垂体激素及发育/调控基因mRNA均受抑制。

要点

  • 14/23(61%)COVID-19死亡者垂体检出SARS-CoV-2基因组和抗原,对照组未检出
  • 病毒阳性垂体可见I型干扰素信号激活及中性粒细胞、细胞毒性细胞评分升高
  • 所有COVID-19病例垂体激素及发育/调控基因mRNA受抑制,与病毒是否阳性无关

核心结论

  • 研究支持SARS-CoV-2对人垂体具有嗜性,并鼓励探索COVID-19后的垂体功能障碍。

研究设计与样本

  • 在23例COVID-19死亡者及12例死于创伤或心源性猝死的对照者垂体中检测SARS-CoV-2基因组和抗原,采用实时逆转录聚合酶链反应(PCR)、原位杂交、免疫组化和透射电镜,并以nCounter检测免疫相关及垂体特异基因mRNA。

主要发现

  • COVID-19组14/23(61%)垂体检出SARS-CoV-2基因组和抗原,对照组未检出。
  • 病毒阳性垂体腺垂体和神经垂体均经PCR持续检出病毒基因组,免疫组化、原位杂交和透射电镜证实病毒存在。
  • 病毒阳性腺体可见I型干扰素信号激活及中性粒细胞和细胞毒性细胞评分升高。
  • 所有COVID-19病例(无论病毒是否阳性)垂体激素及垂体发育/调控基因mRNA均受抑制。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Involvement of the pituitary gland in SARS-CoV-2 infection has been clinically suggested by pituitary hormone deficiency in severe COVID-19 cases, by altered serum adrenocorticotropic hormone (ACTH) levels in hospitalized patients, and by cases of pituitary apoplexy. However, the direct viral infection of the gland has not been investigated. OBJECTIVE: To evaluate whether the SARS-CoV-2 genome and antigens could be present in pituitary glands of lethal cases of COVID-19, and to assess possible changes in the expression of immune-related and pituitary-specific genes. METHODS: SARS-CoV-2 genome and antigens were searched in the pituitary gland of 23 patients who died from COVID-19 and, as controls, in 12 subjects who died from trauma or sudden cardiac death. Real-time reverse transcription polymerase chain reaction (PCR), in situ hybridization, immunohistochemistry, and transmission electron microscopy were utilized. Levels of mRNA transcripts of immune-related and pituitary-specific genes were measured by the nCounter assay. RESULTS: The SARS-CoV-2 genome and antigens were detected in 14/23 (61%) pituitary glands of the COVID-19 group, not in controls. In SARS-CoV-2-positive pituitaries, the viral genome was consistently detected by PCR in the adeno- and the neurohypophysis. Immunohistochemistry, in situ hybridization, and transmission electron microscopy confirmed the presence of SARS-CoV-2 in the pituitary. Activation of type I interferon signaling and enhanced levels of neutrophil and cytotoxic cell scores were found in virus-positive glands. mRNA transcripts of pituitary hormones and pituitary developmental/regulatory genes were suppressed in all COVID-19 cases irrespective of virus positivity. CONCLUSION: Our study supports the tropism of SARS-CoV-2 for human pituitary and encourages exploration of pituitary dysfunction after COVID-19.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Poma AM, Proietti A, Macerola E, et al. Suppression of Pituitary Hormone Genes in Subjects Who Died From COVID-19 Independently of Virus Detection in the Gland. J Clin Endocrinol Metab. 2022. PMID: 35567590. doi:10.1210/clinem/dgac312

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。